Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2989424 | 0.94 | ALDH1A1 (0.71) | HPGDALDH1A1SMN1; SMN2GAAMAPT | |
| SCHEMBL2989637 | 0.73 | ALDH1A1 (0.51) | HPGDALDH1A1SMN1; SMN2GAAKDM4E | |
| SCHEMBL2989640 | 0.73 | ALDH1A1 (0.51) | HPGDALDH1A1SMN1; SMN2GAAKDM4E | |
| SCHEMBL2989634 | 0.73 | ALDH1A1 (0.51) | HPGDALDH1A1SMN1; SMN2GAAKDM4E | |
| SCHEMBL2861582 | 0.73 | HPGD (0.67) | HPGDALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2993849 | 0.72 | ALDH1A1 (0.53) | HPGDALDH1A1SMN1; SMN2GAAKDM4E | |
| SCHEMBL2992964 | 0.71 | ALDH1A1 (1.00) | HPGDALDH1A1SMN1; SMN2GAAKDM4E | |
| SCHEMBL2992155 | 0.70 | TP53 (0.60) | HPGDALDH1A1SMN1; SMN2GAAKDM4E | |
| SCHEMBL2994182 | 0.70 | ALDH1A1 (0.55) | HPGDALDH1A1SMN1; SMN2GAAKDM4E | |
| SCHEMBL250413 | 0.66 | PTGS2 (0.75) | ALDH1A1SMN1; SMN2GAAKDM4EPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184811-A1 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | BRIDGE BIORESEARCH RIGHTS (JERSEY) LIMITED (GB) | 2010-07-22 | — | — | US | disclosed |
| EP-2068873-A2 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | Pharma 2100 (DK) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008031440-A2 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | PHARMA 2100 (DK) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184811-A1 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | ODC1, OTC, ACACB | HPGD 83/4885ALDH1A1 302/4885NPC1 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.